共 11 条
[1]
Introduction: Precision Medicine for Glomerular Disease: The Road Forward
[J].
SEMINARS IN NEPHROLOGY,
2015, 35 (03)
:209-211
Kretzler, Matthias
;
Sedor, John R.
.
[2]
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
[J].
NEW ENGLAND JOURNAL OF MEDICINE,
2014, 371 (23)
:2189-2199
Snyder, Alexandra
;
Makarov, Vladimir
;
Merghoub, Taha
;
Yuan, Jianda
;
Zaretsky, Jesse M.
;
Desrichard, Alexis
;
Walsh, Logan A.
;
Postow, Michael A.
;
Wong, Phillip
;
Ho, Teresa S.
;
Hollmann, Travis J.
;
Bruggeman, Cameron
;
Kannan, Kasthuri
;
Li, Yanyun
;
Elipenahli, Ceyhan
;
Liu, Cailian
;
Harbison, Christopher T.
;
Wang, Lisu
;
Ribas, Antoni
;
Wolchok, Jedd D.
;
Chan, Timothy A.
.
[3]
Cancer beyond organ and tissue specificity: Next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers
[J].
INTERNATIONAL JOURNAL OF CANCER,
2014, 135 (10)
:2362-2369
Heim, D.
;
Budczies, J.
;
Stenzinger, A.
;
Treue, D.
;
Hufnagl, P.
;
Denkert, C.
;
Dietel, M.
;
Klauschen, F.
.
[4]
Precision medicine: an approach to R&D for delivering superior medicines to patients.[J]..Clinical and Translational Medicine.2012, 1
[5]
Omics and therapy – A basis for precision medicine.[J].Joseph P. Garay;Joe W. Gray.Molecular Oncology.2012, 2
[6]
New regulatory framework for cancer drug development.[J].Paul S. Jones;David Jones.Drug Discovery Today.2011, 5-6
[7]
ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.[J].Amanda B.Spurdle;SueHealey;AndrewDevereau;Frans B. L.Hogervorst;Alvaro N. A.Monteiro;Katherine L.Nathanson;PaoloRadice;DominiqueStoppa‐Lyonnet;SeanTavtigian;BarbaraWappenschmidt;Fergus J.Couch;David E.Goldgar.Hum. Mutat..2011, 1
[8]
[9]
[10]